Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 21

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 21
---
 the costs of preparing,                                                                                                           
 filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual 
 property-related claims; and                                                                                                      |

| ● | the level of revenue, if                                                                               
 any, received from commercial sales of any product candidates for which we receive marketing approval. |

Any additional fundraising
efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our Gelrin hydrogel platform and any future product candidates and any future product candidates. In addition, we cannot guarantee that
future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing
may adversely affect the holdings or the rights of holders of our securities and the issuance of additional securities, whether equity
or debt, by us, or the possibility of such issuance, may cause the market price of our Ordinary Shares to decline. The incurrence of
indebtedness could result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such
as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property
rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to
seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable, and we
may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us,
any of which may have a material adverse effect on our business, operating results and prospects. Even if we believe that we have sufficient
funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific
strategic considerations.

If we are unable to obtain
funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development
programs or the development or commercialization, if any, of our Gelrin hydrogel platform and any future product candidates, or any other
product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could
materially affect our business, financial condition and results of operations.

Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.

Our audited financial